Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy

According to the authors of recent research published in the journal Therapeutic Apheresis and Dialysis, "The efficacy of double filtration plasmapheresis (DFPP) plus interferon (IFN)-(SZ ligature) induction therapy was preliminarily investigated in re-treated patients with chronic genotype 1b hepatitis C and high viral load (patients with relapse or non-response to previous IFN therapies). In eight patients with chronic hepatitis C, DFPP was performed five times over 2 weeks during IFN-(SZ ligature) therapy, and 3 MU of IFN-(SZ ligature) was administered twice a day for 2 weeks."

"Combination therapies with ribavirin and pegylated IFN-a2b (PEG-IFN-a2b) or pegylated IFN-a2a (PEG-IFN-a2a) were subsequently used. After 4 weeks, hepatitis C virus (HCV)-RNA tended to be more greatly decreased with DFPP combination therapy than with previous IFN therapy (4.5 (+-) 2.0 log(10) IU/mL vs. 2.9 (+-) 1.2 log(10) IU/mL). Rates of both rapid virological response and complete early virological response were significantly higher with DFPP and IFN-(SZ ligature) induction therapy than with previous IFN therapy. DFPP plus IFN-(SZ ligature) induction therapy produced a great reduction of viral load during the early stage of treatment and achieved a high early virological response, suggesting that this combination therapy may be useful as a new treatment modality for chronic hepatitis C patients in difficult-to-treat states. This combination may contribute to sustained virological response (SVR)," wrote T. Ishikawa and colleagues, Daini Hospital. The researchers concluded: "The effects of DFPP on SVR and its significance remain to be clarified."

Source: Hepatitis Weekly, February 13th, 2012